Technology Transfer: Return on Research Investment

Benefits and Impact Results from a survey released Dec. 2 by the Association of University Technology Managers (AUTM) indicate that federally sponsored research really does pay off, even if it takes years to do so. For the fiscal year ending June 30, 1998, the AUTM survey credits $33.5 billion of U.S. economic activity to technology transfer. That activity included support for 280,000 jobs, issuance of 3,668 new licenses and options, and granting of 3,224 new U.S. patents (see chart). AUTM def

Written byLarry Hand
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Benefits and Impact

Results from a survey released Dec. 2 by the Association of University Technology Managers (AUTM) indicate that federally sponsored research really does pay off, even if it takes years to do so. For the fiscal year ending June 30, 1998, the AUTM survey credits $33.5 billion of U.S. economic activity to technology transfer.

That activity included support for 280,000 jobs, issuance of 3,668 new licenses and options, and granting of 3,224 new U.S. patents (see chart). AUTM defines technology transfer as "the patenting and licensing of discoveries and inventions made in academic research and the movement of these research results from the laboratory to the commercial sector for the public good." Much of the initial research taking place at universities is federally funded.

AUTM president Louis P. Berneman, managing director of the center for technology transfer at the University of Pennsylvania, describes the technology transfer process as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies